ACADIA PHARMACEUTICALS INC (ACAD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 400M 800M 1.2B FY16: 17.3M FY17: 124.9M FY18: 223.8M FY19: 339.1M FY20: 441.8M FY21: 484.1M FY22: 517.2M FY23: 726.4M FY24: 957.8M FY25: 1.1B FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 250M 500M 750M FY16: 14.3M FY17: 115.8M FY18: 211.4M FY19: 327.7M FY20: 431.5M FY21: 473.3M FY22: 507.1M FY23: 684.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23

Operating Income Annual

-300M -200M -100M 0 100M 200M 300M FY16: -272.8M FY17: -292.4M FY18: -247.4M FY19: -246.5M FY20: -286.6M FY21: -170.4M FY22: -223.6M FY23: -73.4M FY24: 230.8M FY25: 104.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-300M -150M 0 150M 300M 450M FY16: -271.4M FY17: -289.4M FY18: -245.2M FY19: -235.3M FY20: -281.6M FY21: -167.9M FY22: -216M FY23: -61.3M FY24: 226.5M FY25: 391M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 35M 70M 105M FY17: 9.1M FY18: 12.4M FY19: 11.3M FY20: 10.2M FY21: 19.1M FY22: 10.2M FY23: 41.6M FY24: 81.8M FY25: 89M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-240M -160M -80M 0 80M 160M 240M FY16: -208.4M FY17: -217.8M FY18: -167.5M FY19: -151.1M FY20: -136.2M FY21: -125.7M FY22: -114M FY23: 16.7M FY24: 157.7M FY25: 109.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-240M -160M -80M 0 80M 160M 240M FY16: -209.9M FY17: -218.6M FY18: -169.6M FY19: -152.3M FY20: -143.8M FY21: -126.8M FY22: -114M FY23: 16.7M FY24: 157.2M FY25: 105.1M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 60M 120M 180M FY09: 37.5M FY10: 38.7M FY11: 52.2M FY12: 55.1M FY20: 157.3K FY21: 160.5K FY22: 161.7M FY23: 163.8M FY24: 166.4M FY25: 169.9M FY09 FY10 FY11 FY12 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q1 '14: -0.55 Q2 '14: -0.66 Q3 '14: -0.79 Q4 '14: -0.94 Q1 '15: -1.15 Q2 '15: -1.32 Q3 '15: -1.46 Q4 '15: -1.63 Q1 '16: -1.68 Q2 '16: -1.92 Q3 '16: -2.14 Q4 '16: -2.34 Q1 '17: -2.61 Q2 '17: -2.53 Q3 '17: -2.45 Q4 '17: -2.35 Q1 '18: -2.07 Q2 '18: -2.03 Q3 '18: -2.00 Q4 '18: -1.95 Q1 '19: -2.10 Q2 '19: -1.97 Q3 '19: -1.76 Q4 '19: -1.60 Q1 '20: -1.58 Q2 '20: -1.47 Q3 '20: -1.72 Q4 '20: -1.80 Q3 '23: -0.92 Q4 '23: -0.38 Q1 '24: -0.01 Q2 '24: 0.18 Q3 '24: 0.78 Q4 '24: 1.36 Q1 '25: 1.37 Q2 '25: 1.33 Q3 '25: 1.55 Q4 '25: 2.30 Q1 '26: 2.21 Q2 '26: 2.23 Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.